Know Who's Eligible for New COVID-19 Monoclonal Antibodies
Bamlanivimab and casirivimab/imdevimab will be the first meds authorized to treat OUTPATIENTS with COVID-19.
These new monoclonal antibodies block SARS-CoV-2 from entering cells. Both meds are single-dose IV infusions given over 1 hour.
You may be giving these "mabs" in your infusion center or a pop-up site (tent, etc). They're also being administered in long-term care facilities or even patients' homes.